Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-48574 phase 2b long-term extension in ulcerative colitis or Crohn's disease
2022-002593-89Phase 2Active
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of duvakitug in autoimmune colitis and Crohn's disease (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Clinical remission based on modified Mayo score. Started Dec 2022; status: active.
02
Drugs
duvakitug
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2022-002593-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002593-89.